Review



cd3 cd19 double depletion  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd3 cd19 double depletion
    Characterization of CD33xCD28 IgG4-scFv 2 TCE. A, Illustration of a combination of a bispecific TCE targeting TAA1 (CD117) on tumor cells and CD3ε on T cells with a bispecific TCE targeting TAA2 (CD33) on tumor cells and CD28 on T-cells. B, Plasmid map of the CD33xCD28 IgG4-scFv 2 construct. C, Protein structure of the CD33xCD28 IgG 4 -scFv 2 construct. D–F, CD33xCD28 IgG4-scFv 2 analysis by mass spectrometry in nonreduced ( D ) and reduced ( E and F ) conditions. G, Size-exclusion chromatography of CD33xCD28 IgG4-scFv 2 . H, SDS-page analysis of CD33xCD28 IgG4-scFv 2 under nonreducing (NR) and reducing (R) conditions M = protein ladder indicating the molecular size (kDa). I, Binding of CD33xCD28 IgG4-scFv 2 to CD33 on MOLM-14 CD117 High GFP + Luc + cells. J, Binding of CD33xCD28 IgG4-scFv 2 to CD28 on peripheral blood T cells. Binding capacity was assessed by the titration of the bispecific antibody and detected by anti-human IgG antibody. MFI was normalized to background fluorescence. Apparent K D was calculated by nonlinear regression. Mean ± SD from three independent experiments, each plated in duplicates.
    Cd3 Cd19 Double Depletion, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+cd19+double+depletion/pmc13114487-50-4-18?v=Miltenyi+Biotec
    Average 98 stars, based on 33 article reviews
    cd3 cd19 double depletion - by Bioz Stars, 2026-08
    98/100 stars

    Images

    1) Product Images from "Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia"

    Article Title: Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia

    Journal: Cancer Research Communications

    doi: 10.1158/2767-9764.CRC-25-0672

    Characterization of CD33xCD28 IgG4-scFv 2 TCE. A, Illustration of a combination of a bispecific TCE targeting TAA1 (CD117) on tumor cells and CD3ε on T cells with a bispecific TCE targeting TAA2 (CD33) on tumor cells and CD28 on T-cells. B, Plasmid map of the CD33xCD28 IgG4-scFv 2 construct. C, Protein structure of the CD33xCD28 IgG 4 -scFv 2 construct. D–F, CD33xCD28 IgG4-scFv 2 analysis by mass spectrometry in nonreduced ( D ) and reduced ( E and F ) conditions. G, Size-exclusion chromatography of CD33xCD28 IgG4-scFv 2 . H, SDS-page analysis of CD33xCD28 IgG4-scFv 2 under nonreducing (NR) and reducing (R) conditions M = protein ladder indicating the molecular size (kDa). I, Binding of CD33xCD28 IgG4-scFv 2 to CD33 on MOLM-14 CD117 High GFP + Luc + cells. J, Binding of CD33xCD28 IgG4-scFv 2 to CD28 on peripheral blood T cells. Binding capacity was assessed by the titration of the bispecific antibody and detected by anti-human IgG antibody. MFI was normalized to background fluorescence. Apparent K D was calculated by nonlinear regression. Mean ± SD from three independent experiments, each plated in duplicates.
    Figure Legend Snippet: Characterization of CD33xCD28 IgG4-scFv 2 TCE. A, Illustration of a combination of a bispecific TCE targeting TAA1 (CD117) on tumor cells and CD3ε on T cells with a bispecific TCE targeting TAA2 (CD33) on tumor cells and CD28 on T-cells. B, Plasmid map of the CD33xCD28 IgG4-scFv 2 construct. C, Protein structure of the CD33xCD28 IgG 4 -scFv 2 construct. D–F, CD33xCD28 IgG4-scFv 2 analysis by mass spectrometry in nonreduced ( D ) and reduced ( E and F ) conditions. G, Size-exclusion chromatography of CD33xCD28 IgG4-scFv 2 . H, SDS-page analysis of CD33xCD28 IgG4-scFv 2 under nonreducing (NR) and reducing (R) conditions M = protein ladder indicating the molecular size (kDa). I, Binding of CD33xCD28 IgG4-scFv 2 to CD33 on MOLM-14 CD117 High GFP + Luc + cells. J, Binding of CD33xCD28 IgG4-scFv 2 to CD28 on peripheral blood T cells. Binding capacity was assessed by the titration of the bispecific antibody and detected by anti-human IgG antibody. MFI was normalized to background fluorescence. Apparent K D was calculated by nonlinear regression. Mean ± SD from three independent experiments, each plated in duplicates.

    Techniques Used: Plasmid Preparation, Construct, Mass Spectrometry, Size-exclusion Chromatography, SDS Page, Binding Assay, Titration, Fluorescence

    CD33xCD28 IgG4-scFv 2 in combination with CD117xCD3 TCE mediates more effective lysis of primary AML cells. A, Representative flow cytometry plots showing CD117 and CD33 expression on four different primary human AML blast populations (CD45dim) upon coculture with healthy donor–derived T cells at an E:T ratio of approximately 1:1. Cells were incubated with antibody constructs as indicated (CD117xCD3 at the indicated concentrations, in combination with 0.5 nmol/L CD33xCD28 IgG4-scFv 2 or 0.5 nmol/L CD28 IgG4). Plots are shown for 0 and 48 hours. B, Percentage of specific lysis of CD45 dim CD3 − AML blasts of the individual patient samples after 48 hours. C, Combined percentage of CD25 + T cells. D, Combined IFNγ in supernatants of coculture. E, Combined proliferation of T cells. Data represent the mean ± SEM from two independent healthy donor–derived T-cell samples, each plated in duplicate. Statistical significance was determined using two-way ANOVA; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
    Figure Legend Snippet: CD33xCD28 IgG4-scFv 2 in combination with CD117xCD3 TCE mediates more effective lysis of primary AML cells. A, Representative flow cytometry plots showing CD117 and CD33 expression on four different primary human AML blast populations (CD45dim) upon coculture with healthy donor–derived T cells at an E:T ratio of approximately 1:1. Cells were incubated with antibody constructs as indicated (CD117xCD3 at the indicated concentrations, in combination with 0.5 nmol/L CD33xCD28 IgG4-scFv 2 or 0.5 nmol/L CD28 IgG4). Plots are shown for 0 and 48 hours. B, Percentage of specific lysis of CD45 dim CD3 − AML blasts of the individual patient samples after 48 hours. C, Combined percentage of CD25 + T cells. D, Combined IFNγ in supernatants of coculture. E, Combined proliferation of T cells. Data represent the mean ± SEM from two independent healthy donor–derived T-cell samples, each plated in duplicate. Statistical significance was determined using two-way ANOVA; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Techniques Used: Lysis, Flow Cytometry, Expressing, Derivative Assay, Incubation, Construct



    Similar Products

    cd3 cd19 double depletion  (Miltenyi Biotec)
    98
    Miltenyi Biotec cd3 cd19 double depletion
    Characterization of CD33xCD28 IgG4-scFv 2 TCE. A, Illustration of a combination of a bispecific TCE targeting TAA1 (CD117) on tumor cells and CD3ε on T cells with a bispecific TCE targeting TAA2 (CD33) on tumor cells and CD28 on T-cells. B, Plasmid map of the CD33xCD28 IgG4-scFv 2 construct. C, Protein structure of the CD33xCD28 IgG 4 -scFv 2 construct. D–F, CD33xCD28 IgG4-scFv 2 analysis by mass spectrometry in nonreduced ( D ) and reduced ( E and F ) conditions. G, Size-exclusion chromatography of CD33xCD28 IgG4-scFv 2 . H, SDS-page analysis of CD33xCD28 IgG4-scFv 2 under nonreducing (NR) and reducing (R) conditions M = protein ladder indicating the molecular size (kDa). I, Binding of CD33xCD28 IgG4-scFv 2 to CD33 on MOLM-14 CD117 High GFP + Luc + cells. J, Binding of CD33xCD28 IgG4-scFv 2 to CD28 on peripheral blood T cells. Binding capacity was assessed by the titration of the bispecific antibody and detected by anti-human IgG antibody. MFI was normalized to background fluorescence. Apparent K D was calculated by nonlinear regression. Mean ± SD from three independent experiments, each plated in duplicates.
    Cd3 Cd19 Double Depletion, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+cd19+double+depletion/pmc13114487-50-4-18?v=Miltenyi+Biotec
    Average 98 stars, based on 1 article reviews
    cd3 cd19 double depletion - by Bioz Stars, 2026-08
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterization of CD33xCD28 IgG4-scFv 2 TCE. A, Illustration of a combination of a bispecific TCE targeting TAA1 (CD117) on tumor cells and CD3ε on T cells with a bispecific TCE targeting TAA2 (CD33) on tumor cells and CD28 on T-cells. B, Plasmid map of the CD33xCD28 IgG4-scFv 2 construct. C, Protein structure of the CD33xCD28 IgG 4 -scFv 2 construct. D–F, CD33xCD28 IgG4-scFv 2 analysis by mass spectrometry in nonreduced ( D ) and reduced ( E and F ) conditions. G, Size-exclusion chromatography of CD33xCD28 IgG4-scFv 2 . H, SDS-page analysis of CD33xCD28 IgG4-scFv 2 under nonreducing (NR) and reducing (R) conditions M = protein ladder indicating the molecular size (kDa). I, Binding of CD33xCD28 IgG4-scFv 2 to CD33 on MOLM-14 CD117 High GFP + Luc + cells. J, Binding of CD33xCD28 IgG4-scFv 2 to CD28 on peripheral blood T cells. Binding capacity was assessed by the titration of the bispecific antibody and detected by anti-human IgG antibody. MFI was normalized to background fluorescence. Apparent K D was calculated by nonlinear regression. Mean ± SD from three independent experiments, each plated in duplicates.

    Journal: Cancer Research Communications

    Article Title: Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia

    doi: 10.1158/2767-9764.CRC-25-0672

    Figure Lengend Snippet: Characterization of CD33xCD28 IgG4-scFv 2 TCE. A, Illustration of a combination of a bispecific TCE targeting TAA1 (CD117) on tumor cells and CD3ε on T cells with a bispecific TCE targeting TAA2 (CD33) on tumor cells and CD28 on T-cells. B, Plasmid map of the CD33xCD28 IgG4-scFv 2 construct. C, Protein structure of the CD33xCD28 IgG 4 -scFv 2 construct. D–F, CD33xCD28 IgG4-scFv 2 analysis by mass spectrometry in nonreduced ( D ) and reduced ( E and F ) conditions. G, Size-exclusion chromatography of CD33xCD28 IgG4-scFv 2 . H, SDS-page analysis of CD33xCD28 IgG4-scFv 2 under nonreducing (NR) and reducing (R) conditions M = protein ladder indicating the molecular size (kDa). I, Binding of CD33xCD28 IgG4-scFv 2 to CD33 on MOLM-14 CD117 High GFP + Luc + cells. J, Binding of CD33xCD28 IgG4-scFv 2 to CD28 on peripheral blood T cells. Binding capacity was assessed by the titration of the bispecific antibody and detected by anti-human IgG antibody. MFI was normalized to background fluorescence. Apparent K D was calculated by nonlinear regression. Mean ± SD from three independent experiments, each plated in duplicates.

    Article Snippet: In selected cases, a CD3 + /CD19 + double depletion was performed using human CD3 and CD19 MicroBeads (Miltenyi Biotec, cat. #130-136-718), following the manufacturer’s protocol.

    Techniques: Plasmid Preparation, Construct, Mass Spectrometry, Size-exclusion Chromatography, SDS Page, Binding Assay, Titration, Fluorescence

    CD33xCD28 IgG4-scFv 2 in combination with CD117xCD3 TCE mediates more effective lysis of primary AML cells. A, Representative flow cytometry plots showing CD117 and CD33 expression on four different primary human AML blast populations (CD45dim) upon coculture with healthy donor–derived T cells at an E:T ratio of approximately 1:1. Cells were incubated with antibody constructs as indicated (CD117xCD3 at the indicated concentrations, in combination with 0.5 nmol/L CD33xCD28 IgG4-scFv 2 or 0.5 nmol/L CD28 IgG4). Plots are shown for 0 and 48 hours. B, Percentage of specific lysis of CD45 dim CD3 − AML blasts of the individual patient samples after 48 hours. C, Combined percentage of CD25 + T cells. D, Combined IFNγ in supernatants of coculture. E, Combined proliferation of T cells. Data represent the mean ± SEM from two independent healthy donor–derived T-cell samples, each plated in duplicate. Statistical significance was determined using two-way ANOVA; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Journal: Cancer Research Communications

    Article Title: Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia

    doi: 10.1158/2767-9764.CRC-25-0672

    Figure Lengend Snippet: CD33xCD28 IgG4-scFv 2 in combination with CD117xCD3 TCE mediates more effective lysis of primary AML cells. A, Representative flow cytometry plots showing CD117 and CD33 expression on four different primary human AML blast populations (CD45dim) upon coculture with healthy donor–derived T cells at an E:T ratio of approximately 1:1. Cells were incubated with antibody constructs as indicated (CD117xCD3 at the indicated concentrations, in combination with 0.5 nmol/L CD33xCD28 IgG4-scFv 2 or 0.5 nmol/L CD28 IgG4). Plots are shown for 0 and 48 hours. B, Percentage of specific lysis of CD45 dim CD3 − AML blasts of the individual patient samples after 48 hours. C, Combined percentage of CD25 + T cells. D, Combined IFNγ in supernatants of coculture. E, Combined proliferation of T cells. Data represent the mean ± SEM from two independent healthy donor–derived T-cell samples, each plated in duplicate. Statistical significance was determined using two-way ANOVA; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

    Article Snippet: In selected cases, a CD3 + /CD19 + double depletion was performed using human CD3 and CD19 MicroBeads (Miltenyi Biotec, cat. #130-136-718), following the manufacturer’s protocol.

    Techniques: Lysis, Flow Cytometry, Expressing, Derivative Assay, Incubation, Construct